Molecular Breast Imaging: Effect of Menstrual Cycle, Hormone Therapy, and Tamoxifen on Tc-99m Sestamibi Uptake in the Breast.

Mayo Clinic1 site in 1 country110 target enrollmentJanuary 2008

Overview

This study is to examine the effects of menstrual cycle, hormone therapy, and the use of tamoxifen on Tc-99m sestamibi uptake.

Registry

clinicaltrials.gov

Start Date

January 2008

End Date

January 2012

Last Updated

14 years ago

Study Type

Observational

Sex

Female

Sponsor

Responsible Party

Principal Investigator

Deborah Rhodes

Mayo Clinic

•age 35-45
•have regular menstrual cycles as defined by having menstrual cycle length of 25-31 days, with menstrual flow of 2-7 days, and no intermenstrual spotting or bleeding.
•have had a negative screening mammogram within one year prior to the MBI studies that is available for comparison.

•currently using any exogenous hormones (e.g., hormonal contraceptives, sex steroid hormones) or any estrogen receptor modulating drugs (e.g., tamoxifen, raloxifene) or any aromatase inhibitors
•have a personal history of any cancer, except non-melanomatous skin cancer
•unable to understand and sign the consent form
•pregnant or lactating
•physically unable to sit upright and still for 30 minutes
•Inclusion Criteria:
•scheduled to begin one of the following regimens of HT:
•Any dosage of any formulation of systemic estrogen therapy in the setting of a prior hysterectomy
•Any dosage of continuous estrogen plus monthly, cyclic progesterone therapy where the progesterone therapy is the oral, micronized formulation
•had a negative screening mammogram within one year prior to the MBI studies that is available for comparison.